Type of security: Stock
Sector: Health Care
Industry: Major Pharmaceuticals
The data is delayed by 15 minutes.
AKRX is in the long-term up 276% in 25 years.
Description: Akorn, Inc. manufactures and markets diagnostic and therapeutic ophthalmic pharmaceuticals, niche hospital drugs, and injectable pharmaceuticals in the United States and internationally. It offers products in various areas, including ophthalmology, antidotes, anti-infectives, pain management, anesthesia, vaccines, and others. The company operates in three segments: Ophthalmic, Hospital Drugs & Injectables, and Contract Services. The Ophthalmic segment markets diagnostic products, such as mydriatics and cycloplegics, anesthetics, topical stains, gonioscopic solutions, angiography dyes, and others for use in the office setting; therapeutic products, including antibiotics, steroids, steroid combinations, glaucoma medications, decongestants/antihistamines, and anti-edema medications to wholesalers, chain drug stores, and other national account customers; non-pharmaceutical products comprising artificial tear solutions, preservative-free lubricating ointments, and eyelid cleansers; and over-the-counter dry eye and
See how to gain 20% in 14 sec with TrendsInvesting
|Shares Outstanding||EPS||1.68||EPS Growth - 4 Quarters||EPS Growth - Q/Q|
|EPS Growth - Y/Y||Sales Growth - 4 Quarters||151.41%||Sales Growth - Q/Q||71.65%||P/E||19.93|
|P/E To EPS Growth||P/S||P/BV||Price/Cash Per Share|
|Price/Free Cash Flow||ROA||1.85%||ROE||9.14%||ROI|
|Current Ratio||3.68||Quick Ratio||2.71||Long Term Debt/Equity||3.1||Debt Ratio||0.35|
|Gross Margin||50.18%||Operating Margin||16.31%||Net Profit Margin||5.96%||Dividend Payout Ratio|
|Cash From Financing Activities||972.31 M||Cash From Investing Activities||-966.54 M||Cash From Operating Activities||30.92 M||Gross Profit||128.38 M|
|Net Profit||34.23 M||Operating Profit||71.91 M||Total Assets||1.91 B||Total Current Assets||494.33 M|
|Total Current Liabilities||134.16 M||Total Debt||1.12 B||Total Liabilities||1.52 B||Total Revenue||227.83 M|
|High 52 week||33.56||Low 52 week||3.33||Last close||3.64||Last change||-5.94%|
|RSI||48.76||Average true range||0.32||Beta||0.93||Volume||2.35 M|
|Simple moving average 20 days||-0.15%||Simple moving average 50 days||-30.37%||Simple moving average 200 days||-72.33%|
|Performance Week||4.6%||Performance Month||-17.65%||Performance Quart||-41.85%||Performance Half||-74.07%|
|Performance Year||-89.13%||Performance Year-to-date||7.37%||Volatility daily||5.48%||Volatility weekly||12.26%|
|Volatility monthly||25.12%||Volatility yearly||87.01%||Relative Volume||219.78%||Average Volume||3.71 M|
|New High||New Low|
2020-05-28 11:14:57 | WeWork Board Factions Head for Clash Over New Directors
2020-05-26 12:42:08 | Akorn, Inc. -- Moody's downgrades Akorn's PDR to D-PD following Chapter 11 filing
2020-05-22 13:37:14 | Akorn Seeks Bankruptcy After Failed Takeover, FDA Warnings
2020-05-21 12:21:00 | Akorn Files Chapter 11 After Failure to Be Acquired
2020-05-21 07:56:09 | Akorn Plummets 27% In Pre-Market On Bankruptcy Filing
2020-05-20 23:52:00 | Akorn to Use Voluntary Chapter 11 Process to Position Business for Long-Term Success
2020-05-20 20:12:53 | Forescout sues Advent to complete $1.9 billion merger
2020-05-11 17:14:47 | Akorn Provides First Quarter 2020 Results
2020-04-07 11:24:49 | WeWork Directors Sue SoftBank Over Decision to Abandon Deal
2020-04-02 15:59:45 | Bed Bath sues 1-800-Flowers for trying to renege on deal over COVID-19
2020-04-01 06:20:00 | Akorn Provides Update on Sale Process
2020-02-29 07:20:45 | US$4.00: That's What Analysts Think Akorn, Inc. Is Worth After Its Latest Results
2020-02-26 16:58:47 | Akorn Provides Fourth Quarter and Full Year 2019 Results
2020-02-19 09:55:02 | Akorn AKRX to Report Q4 Earnings: What's in the Cards?
2020-02-10 07:00:00 | Akorn Continues Negotiations with Lenders
2020-01-31 07:12:43 | How Many Akorn, Inc. NASDAQ:AKRX Shares Did Insiders Buy, In The Last Year?
2019-12-19 09:26:02 | Akorn Enters Oversold Territory
2019-12-16 07:51:52 | Akorn Announces Extension of Standstill Agreement
2019-12-11 13:54:53 | Is Akorn, Inc. AKRX Going To Burn These Hedge Funds ?
2019-11-28 09:00:02 | Akorn AKRX Moves to Strong Buy: Rationale Behind the Upgrade
2019-11-26 08:36:01 | Generic Drugmakers Gain as Price-Fixing Probe Nears an End
2019-11-19 16:54:22 | Teva, Bausch Could Be Next to File for Bankruptcy
2019-11-12 08:27:01 | The Zacks Analyst Blog Highlights: Forterra, Barrett Business, Chuy's, Akorn and Quanex
2019-11-11 07:03:12 | 5 Small-Cap Stocks Outpacing the Broader Market in 2019
2019-11-07 08:22:01 | New Strong Buy Stocks for November 7th
2019-11-05 19:00:00 | Akorn to Present at the Credit Suisse Healthcare Conference
2019-10-31 23:04:35 | Edited Transcript of AKRX earnings conference call or presentation 31-Oct-19 2:00pm GMT
2019-10-31 08:35:12 | Akorn AKRX Q3 Earnings and Revenues Top Estimates
2019-10-31 07:00:05 | Akorn Provides Preliminary Third Quarter 2019 Results
2019-10-24 10:32:02 | Will Akorn AKRX Report Negative Earnings Next Week? What You Should Know
2019-10-17 09:00:01 | All You Need to Know About Akorn AKRX Rating Upgrade to Buy
2019-10-14 16:25:00 | Akorn Receives FDA Approval for Betamethasone Dipropionate Lotion USP Augmented, 0.05%
2019-10-14 13:05:00 | Akorn to Report Third Quarter 2019 Financial Results and Host Conference Call
2019-09-29 08:36:40 | Should You Be Concerned About Akorn, Inc.'s NASDAQ:AKRX Historical Volatility?
2019-08-26 13:35:36 | Akorn Receives FDA Approval for Azelastine Hydrochloride Nasal Spray, 0.15%
2019-08-14 15:30:05 | Is Akorn NASDAQ:AKRX A Risky Investment?
2019-08-05 16:15:04 | Edited Transcript of AKRX earnings conference call or presentation 1-Aug-19 1:00pm GMT
2019-08-02 07:24:08 | Akorn AKRX Q2 2019 Earnings Call Transcript
2019-08-01 08:55:12 | Akorn AKRX Reports Q2 Loss, Tops Revenue Estimates
2019-07-25 10:33:02 | Analysts Estimate Akorn AKRX to Report a Decline in Earnings: What to Look Out for
2019-07-11 16:32:15 | Akorn to Report Second Quarter 2019 Financial Results and Host Conference Call
2019-07-09 08:02:30 | See what the IHS Markit Score report has to say about Akorn Inc.
2019-06-28 07:00:00 | Akorn Announces Launch of Loteprednol Etabonate Ophthalmic Suspension, 0.5%